secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-174958
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics Q2 net loss widens to $27.4M; cash $114.2M, divesiran Phase 2 on track
--------------------------------------------------------------------------------

- Net loss of $27.4M in Q2 2025 vs $19.8M in Q2 2024; R&D expenses rose to $17.6M.
- Cash and short-term investments $114.2M as of June 30, 2025; expected to fund operations into 2028.
- Divesiran Phase 2 SANRECO trial >50% enrolled; on track for full enrollment by year-end 2025.
- Paused Phase 1 initiation of SLN548 to prioritize extra-hepatic siRNA targeting; preclinical data promising.
- Zerlasiran Phase 3 readiness activities completed; seeking partnership for Phase 3 and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/0001193125-25-174958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/d14149d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer